NCT01190930

Clinical Trial Information

Trial Number: NCT01190930 (ClinicalTrials.gov)

Disease Type:

Hematopoietic Neoplasm/Leukemia - Acute Lymphoblastic Leukemia
Hematopoietic Neoplasm/Lymphoma - Non-Hodgkin Lymphoma

Trial Title:

Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy)

Study ID:

AALL0932

Images are available?:

Is this a NCI-MATCH Trial?:

Datasets Linked to Trial

Title	Description
NCT01190930-D2	There are 2 data submissions (NCT01190930-D1, and -D2) for PMID 33411585. This dataset, NCT01190930-D2, contains information on targeted adverse event for Induction, AR Postinduction Premaintenance and AR Maintenance, and AR Maintenance by treatment arm presented in Tables A6 and A7. The data cutoff is 06/30/2019.
NCT01190930-D1	There are 2 data submissions (NCT01190930-D1, and -D2) for PMID 33411585. This dataset, NCT01190930-D1, contains the information on patient enrollment, patient characteristics, event-free survival/disease-free survival/overall survival analysis, cumulative incidence of relapse, SMN and death, induction death, induction failure, and sites of relapses by pulse frequency, oral methotrexate dose and AR maintenance arm presented in Figures 2, 3, 4, A1, A2, A3 and Tables 2, 3, A5. There is one row for each patient enrolled. The data cutoff is 06/30/2019.

Title

Description

NCT01190930-D2

There are 2 data submissions (NCT01190930-D1, and -D2) for PMID 33411585. This dataset, NCT01190930-D2, contains information on targeted adverse event for Induction, AR Postinduction Premaintenance and AR Maintenance, and AR Maintenance by treatment arm presented in Tables A6 and A7. The data cutoff is 06/30/2019.

NCT01190930-D1

There are 2 data submissions (NCT01190930-D1, and -D2) for PMID 33411585. This dataset, NCT01190930-D1, contains the information on patient enrollment, patient characteristics, event-free survival/disease-free survival/overall survival analysis, cumulative incidence of relapse, SMN and death, induction death, induction failure, and sites of relapses by pulse frequency, oral methotrexate dose and AR maintenance arm presented in Figures 2, 3, 4, A1, A2, A3 and Tables 2, 3, A5. There is one row for each patient enrolled. The data cutoff is 06/30/2019.

Accessibility | Disclaimer | FOIA | HHS Vulnerability Disclosure | Privacy & Security

U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute | USA.gov

NIH…Turning Discovery Into Health^®